*ST辉丰(002496.SZ)拟出售母公司业务 构成重大资产重组
*ST辉丰(002496.SZ)公布,公司拟将母公司的化学农药产品、化学农药中间体产品和制剂产品的开发、生产、制剂加工、销售和市场营销业务51%的控制权出售给安道麦A(000553.SZ),但是用於生物激活素的(口塞)苯隆系列产品、微生物系列药肥产品及联苯菊酯原药业务除外。
辉丰股份拟将母公司的原药业务和制剂生产业务所需的全部资产等置入其100%持股的科利农,向安道麦转让重组後的科利农51%股权;拟将制剂销售业务(包含新疆辉丰生物科技有限公司100%股权)置入其100%持股的上海迪拜植保,向安道麦转让重组後的上海迪拜51%股权。此次交易构成重大资产重组。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.